Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer

Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer

EMJ

3 years
595 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, explains the rationale and design of PlanB, a prospective phase 3 trial evaluating the Oncotype DX® 21-gene Recurrence Score® result for defining a low-risk subgroup of breast cancer patients with node-negative disease and high-risk clinicopathological factors as well as patients with node-positive disease who could be treated with adjuvant endocrine therapy alone. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research  through study of von Hippel-Lindau (VHL) disease
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 13 hours
Re-evaluating TKI in CML Patients During Pregnancy
Re-evaluating TKI in CML Patients During Pregnancy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Category: Acute Myelogenous Leukemia
2 Views
Cancer-News 13 hours
CML and Pregnancy
CML and Pregnancy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 14 hours
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
Category: Acute Lymphoblastic Leukemia
3 Views
Cancer-News 14 hours
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
Category: Chronic Lymphocytic Leukemia
2 Views
Cancer-News 14 hours
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
4 Views
Cancer-News 14 hours
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Category: News
1 Views
Cancer-News 14 hours